Bvf Incil Lowers stake in CytomX Therapeutics Inc (CTMX)

CytomX Therapeutics Inc (CTMX) : Bvf Incil reduced its stake in CytomX Therapeutics Inc by 0.45% during the most recent quarter end. The investment management company now holds a total of 606,138 shares of CytomX Therapeutics Inc which is valued at $6,758,439 after selling 2,710 shares in CytomX Therapeutics Inc , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.CytomX Therapeutics Inc makes up approximately 1.52% of Bvf Incil’s portfolio.

Other Hedge Funds, Including , Regents Of The University Of California added CTMX to its portfolio by purchasing 71,366 company shares during the most recent quarter which is valued at $795,731. CytomX Therapeutics Inc makes up approx 2.46% of Regents Of The University Of California’s portfolio.Geode Capital Management boosted its stake in CTMX in the latest quarter, The investment management firm added 7,860 additional shares and now holds a total of 76,114 shares of CytomX Therapeutics Inc which is valued at $848,671.Teachers Advisors Inc boosted its stake in CTMX in the latest quarter, The investment management firm added 25,089 additional shares and now holds a total of 32,752 shares of CytomX Therapeutics Inc which is valued at $365,185.New York State Common Retirement Fund boosted its stake in CTMX in the latest quarter, The investment management firm added 13,600 additional shares and now holds a total of 20,900 shares of CytomX Therapeutics Inc which is valued at $233,035.Blackrock Investment Management boosted its stake in CTMX in the latest quarter, The investment management firm added 49,279 additional shares and now holds a total of 76,710 shares of CytomX Therapeutics Inc which is valued at $855,317.

CytomX Therapeutics Inc. is a United States-based biotechnology company. The Company is engaged in developing Probody therapeutics for the treatment of cancer. Its Probody Platform designs drugs which activate in the tumor microenvironment while remaining inert in tissue and in circulation. It is also engaged in discovering and developing immunotherapy and antibody drug conjugate therapies to treat areas of medical need in oncology. The Company also focuses on applying its technology to bispecific T-cell engaging antibodies and engineered cell therapies. The Company’s pipeline focuses in two areas in research and development: Precision cancer immunotherapy and Probody drug conjugates (PDCs). The Company’s additional pipeline programs include Probody applications in the field of bispecific antibodies and engineered cell therapies.

Leave a Reply

CytomX Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on CytomX Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.